BACKGROUND: Currently liver resection offers the only potential cure for colorectal liver metastases (CRLM). We prospectively audited the outcome of CRLM treated by a combination of neo-adjuvant chemotherapy and surgery. METHODS: 283 consecutive patients underwent liver resection for CRLM over 10 years with curative intent. Patients received chemotherapy preoperatively for synchronous and early (< 2 years) metachronous metastases. Univariate and multivariate analyses were used to identify mortality risk factors. RESULTS: Overall survival at 1, 3 and 5 years was 90%, 59.2% and 46.1%, respectively. Disease free survival at 1, 3 and 5 years was 68.1%, 34.8% and 27.9%, respectively. Operative mortality was 2.1% and morbidity was 23.7%. Patients with macroscopic diaphragm invasion by tumour, CEA > 100 ng/ml, tumour size > 5 cm or cancer involved resection margins (CIRM) had a significantly worse overall survival. Incidence of CIRM and re-resection was 4.9% and 4.5%, respectively. CONCLUSIONS: Neo-adjuvant chemotherapy followed by liver surgery is associated with improved survival and low CIRM and re-resection rates.
BACKGROUND: Currently liver resection offers the only potential cure for colorectal liver metastases (CRLM). We prospectively audited the outcome of CRLM treated by a combination of neo-adjuvant chemotherapy and surgery. METHODS: 283 consecutive patients underwent liver resection for CRLM over 10 years with curative intent. Patients received chemotherapy preoperatively for synchronous and early (< 2 years) metachronous metastases. Univariate and multivariate analyses were used to identify mortality risk factors. RESULTS: Overall survival at 1, 3 and 5 years was 90%, 59.2% and 46.1%, respectively. Disease free survival at 1, 3 and 5 years was 68.1%, 34.8% and 27.9%, respectively. Operative mortality was 2.1% and morbidity was 23.7%. Patients with macroscopic diaphragm invasion by tumour, CEA > 100 ng/ml, tumour size > 5 cm or cancer involved resection margins (CIRM) had a significantly worse overall survival. Incidence of CIRM and re-resection was 4.9% and 4.5%, respectively. CONCLUSIONS: Neo-adjuvant chemotherapy followed by liver surgery is associated with improved survival and low CIRM and re-resection rates.
Authors: Boudewijn E Schaafsma; J Sven D Mieog; Merlijn Hutteman; Joost R van der Vorst; Peter J K Kuppen; Clemens W G M Löwik; John V Frangioni; Cornelis J H van de Velde; Alexander L Vahrmeijer Journal: J Surg Oncol Date: 2011-04-14 Impact factor: 3.454
Authors: William J Hadden; Philip R de Reuver; Kai Brown; Anubhav Mittal; Jaswinder S Samra; Thomas J Hugh Journal: HPB (Oxford) Date: 2016-02-01 Impact factor: 3.647
Authors: H J M Handgraaf; L S F Boogerd; D J Höppener; A Peloso; B G Sibinga Mulder; C E S Hoogstins; H H Hartgrink; C J H van de Velde; J S D Mieog; R J Swijnenburg; H Putter; M Maestri; A E Braat; J V Frangioni; A L Vahrmeijer Journal: Eur J Surg Oncol Date: 2017-05-06 Impact factor: 4.424
Authors: Joost R van der Vorst; Boudewijn E Schaafsma; Merlijn Hutteman; Floris P R Verbeek; Gerrit-Jan Liefers; Henk H Hartgrink; Vincent T H B M Smit; Clemens W G M Löwik; Cornelis J H van de Velde; John V Frangioni; Alexander L Vahrmeijer Journal: Cancer Date: 2013-06-21 Impact factor: 6.860
Authors: Bruno C Odisio; Suguru Yamashita; Steven Y Huang; Scott E Kopetz; Kamran Ahrar; Takashi Mizuno; Claudius Conrad; Thomas A Aloia; Yun Shin Chun; Sanjay Gupta; Jean-Nicolas Vauthey Journal: J Vasc Interv Radiol Date: 2018-02-01 Impact factor: 3.464
Authors: Jeffrey T Lordan; Tim R Worthington; Nial Quiney; William Fawcett; Nariman D Karanjia Journal: HPB (Oxford) Date: 2009-06 Impact factor: 3.647
Authors: Jeffrey T Lordan; Tim R Worthington; Nial Quiney; William J Fawcett; Nariman D Karanjia Journal: Ann R Coll Surg Engl Date: 2009-08-14 Impact factor: 1.891